Companies: 10,795·Total market cap: $144.5T
Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

ELVNNASDAQHealthcare● Active
$33.80
$-0.91(-2.62%)
Market Cap$2.1B
P/E Ratio
52W High$48.53
52W Low$14.785
Overview

Enliven Therapeutics, Inc. (ELVN) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · ELVN · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.64elvn eps ttm · elvn earnings per shareEarnings history
PE Ratio (TTM)elvn pe ratio ttm · elvn price to earningsPE Ratio deep dive
Revenue (TTM)0.00elvn revenue ttm · elvn annual revenueFull revenue history
Dividend YieldNo Dividenddoes elvn pay dividends · elvn dividend yieldDividend history
Shares Outstanding56.7Melvn shares outstanding · elvn floatShares outstanding history
Next EarningsAug 12, 2026Est.elvn earnings date · elvn next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
enliven therapeutics, inc. revenue · elvn revenue 2025
FY 2025Net Income-$103.7M▼ 16.48% YoY
202320242025
enliven therapeutics, inc. net income · elvn profit 2025
FY 2025EPS$-1.83▲ +3.17% YoY
202320242025
elvn eps · enliven therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$98.8MEPS: $-1.64View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy7 analystsis elvn a buy · elvn analyst rating
Strong Buy
0
Buy
7
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$59.00Low
$33.80Current
$67.00Avg Target98.21% upside
$80.00High
elvn price target · elvn 12 month forecast

Total: 7 · Buy rate: 100.0%

The ELVN analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $67.00, representing +98.21% upside from the current price of $33.80.

Stock Performance

Full History
1D-2.20%
1W-1.95%
1M-14.82%
3M+17.90%
YTD+125.39%
1Y+70.65%
5Y-4.01%

About Enliven Therapeutics, Inc.

CEORichard A. Fair
IPO DateMar 12, 2020
Employees62
CountryUS

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating c…

what is enliven therapeutics, inc. · elvn stock overview · enliven therapeutics, inc. company profile · who is enliven therapeutics, inc. ceo · elvn NASDAQ · enliven therapeutics, inc. headquarters · enliven therapeutics, inc. business segments

About Stock Overview & Key Data

Enliven Therapeutics, Inc. (ELVN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 12, 2020. As of the latest trading session, ELVN stock price is $33.80, with a market capitalization of $2.1B. The stock has returned +70.65% over the past 12 months and +125.39% year-to-date.

According to 7 Wall Street analysts, the consensus rating for Enliven Therapeutics, Inc. stock is Buy, with an average 12-month price target of $67.00. In fiscal year 2025, Enliven Therapeutics, Inc. reported revenue of — and net income of -$103.7M. For detailed data — including Enliven Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Enliven Therapeutics, Inc. (ELVN) stock price is $33.80. The stock is traded on NASDAQ under the ticker symbol ELVN. The 52-week range is $14.79 – $48.53.

ELVN stock priceELVN quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice